A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Inadequately Controlled Asthma and High Bronchodilator Reversibility
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Brodalumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Amgen
- 21 Apr 2015 According to media release, status changed from recruiting to discontinued.
- 23 Nov 2014 Planned End Date changed from 1 Feb 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov.
- 23 Nov 2014 Planned primary completion date changed from 1 Dec 2014 to 1 Jan 2016 as reported by ClinicalTrials.gov.